DBV Technologies to Present at Key March Investor Conferences

Event summary

  • DBV Technologies will participate in two investor conferences in March 2026: Citizens Life Sciences Conference on March 10 and Leerink Partners Global Healthcare Conference on March 11.
  • The Citizens Life Sciences Conference will feature a fireside chat at 1:40pm ET.
  • The Leerink Partners Global Healthcare Conference will include 1-on-1 meetings.
  • DBV Technologies is a late-stage biopharmaceutical company focused on food allergy treatments using its proprietary VIASKIN® patch technology.

The big picture

DBV Technologies' participation in these investor conferences underscores its focus on engaging with the investment community amid critical phases of its clinical trials. The company's proprietary VIASKIN® patch technology positions it uniquely in the food allergy treatment market, which remains underserved. The strategic significance of these conferences lies in their potential to attract new investors and partnerships as DBV Technologies advances its pipeline.

What we're watching

Clinical Progress
How the ongoing clinical trials of VIASKIN Peanut will impact investor sentiment and strategic partnerships.
Market Positioning
Whether DBV Technologies can sustain its lead in the epicutaneous immunotherapy space amid competitive pressures.
Regulatory Pathway
The pace at which regulatory approvals for VIASKIN Peanut could accelerate commercialization efforts.